Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + temozolomide + nanoliposomal irinotecan for recurrent high-grade glioma
ChiCTR2400085193Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab, temozolomide and nanoliposomal irinotecan in glioma, sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Jun 2024; status: recruiting.
02
Drugs
bevacizumabtemozolomidenanoliposomal irinotecan
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2400085193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085193.